Pascal Fenoglietto
University of Montpellier
64 Papers
214 Citations
Pascal Fenoglietto is an academic researcher from University of Montpellier. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 15, co-authored 37 publications. Previous affiliations of Pascal Fenoglietto include French Institute of Health and Medical Research.
Chat about Author
Papers
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial
David Azria,Yazid Belkacemi,Gilles Romieu,Sophie Gourgou,Marian Gutowski,Khalil Zaman,Carmen Llacer Moscardo,Claire Lemanski,Michael Coelho,Barry S. Rosenstein,Pascal Fenoglietto,Nigel E A Crompton,Mahmut Ozsahin +12 more
TL;DR: In this article, the authors assessed concurrent and sequential radiotherapy and letrozole in the adjuvant setting in a phase 2 randomised trial with 150 postmenopausal women with early stage breast cancer.
122
Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial.
David Azria,Olivier Riou,Florence Castan,Tan Dat Nguyen,K Peignaux,Claire Lemanski,Jean-Léon Lagrange,Youlia M. Kirova,Eric Lartigau,Yazid Belkacemi,Céline Bourgier,Sofia Rivera,Georges Noël,S. Clippe,Françoise Mornex,Christophe Hennequin,Andrew Kramar,Sophie Gourgou,André Pèlegrin,Pascal Fenoglietto,Esat Mahmut Ozsahin +20 more
TL;DR: This study validates the use of RILA as a rapid screening test before RT delivery and will change definitely the authors' daily clinical practice in radiation oncology.
103
IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center
S. Vieillot,Pascal Fenoglietto,Claire Lemanski,Carmen Llacer Moscardo,Sophie Gourgou,Jean-Bernard Dubois,Norbert Ailleres,David Azria +7 more
TL;DR: IMRT is well tolerated with acceptable treatment interruption allowing dose escalation, and no patient experienced any late grade 4 toxicity with a median follow-up of 24 months.
Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk
Pascal Fenoglietto,Benoit Laliberté,Ali Allaw,Norbert Ailleres,Katia Idri,M.-H. Hay,Carmen Llacer Moscardo,Sophie Gourgou,Jean-Bernard Dubois,David Azria +9 more
TL;DR: Dose coverage of the PTV and OAR was better with 3D-IMRT for each patient and remained so after internal volume changes, as measured by non-parametric tests statistics.
40
Prostate Hypofractionated Radiation Therapy With Injection of Hyaluronic Acid: Acute Toxicities in a Phase 2 Study
O. Chapet,Evelyne Decullier,Sylvie Bin,A. Faix,Alain Ruffion,Patrice Jalade,Pascal Fenoglietto,Corina Udrescu,Ciprian Enachescu,David Azria +9 more
TL;DR: The injection of hyaluronic acid makes it possible to deliver hypofractionated irradiation over 4 weeks with a dose per fraction of > 3 Gy, with limited acute rectal toxicity.
33